SELL SELL or SEL SEL?
https://markets.businessinsider.com/news/stocks/selecta-biosciences-presents-full-data-from-phase-2-trial-of-sel-212-for-chronic-refractory-gout-at-eular-2019-1028273246
Selecta making noise about Phase II trials on June 15th. Likely rehashed has, but one has to keep an open mind. Phase III will start later this year (they do have a cash flow problem though). HZNP needs to ensure their study(ies) results come out first, particularly if they are strong. No sense for rheums and nephros to switch from K unless there is a significant upside to an alternate therapy (and I doubt that will be the case when apples to apples when both drugs using immunomoidfiers).